Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 7761 | 1.43 |
09:34 ET | 3765 | 1.425 |
09:36 ET | 2704 | 1.42 |
09:38 ET | 1000 | 1.43 |
09:39 ET | 300 | 1.42 |
09:41 ET | 721 | 1.42 |
09:43 ET | 1961 | 1.42 |
09:45 ET | 400 | 1.44 |
09:48 ET | 5600 | 1.44 |
09:50 ET | 609 | 1.435 |
09:52 ET | 4555 | 1.43 |
09:54 ET | 549 | 1.435 |
09:56 ET | 520 | 1.44 |
09:57 ET | 1712 | 1.45 |
09:59 ET | 3735 | 1.455 |
10:01 ET | 1200 | 1.46 |
10:03 ET | 300 | 1.46 |
10:06 ET | 5696 | 1.455 |
10:08 ET | 2500 | 1.46 |
10:10 ET | 1000 | 1.455 |
10:12 ET | 889 | 1.46 |
10:14 ET | 600 | 1.46 |
10:15 ET | 200 | 1.46 |
10:17 ET | 310 | 1.455 |
10:19 ET | 600 | 1.455 |
10:21 ET | 200 | 1.46 |
10:24 ET | 500 | 1.46 |
10:26 ET | 300 | 1.46 |
10:28 ET | 10549 | 1.465 |
10:30 ET | 1855 | 1.465 |
10:32 ET | 200 | 1.46 |
10:33 ET | 400 | 1.47 |
10:35 ET | 3020 | 1.47 |
10:37 ET | 4150 | 1.48 |
10:39 ET | 5600 | 1.48 |
10:42 ET | 3100 | 1.485 |
10:44 ET | 1646 | 1.49 |
10:46 ET | 300 | 1.48 |
10:48 ET | 6771 | 1.48 |
10:50 ET | 900 | 1.48 |
10:53 ET | 790 | 1.475 |
10:55 ET | 700 | 1.48 |
10:57 ET | 325 | 1.475 |
11:00 ET | 600 | 1.48 |
11:02 ET | 1520 | 1.48 |
11:04 ET | 500 | 1.485 |
11:06 ET | 8500 | 1.485 |
11:08 ET | 18097 | 1.51 |
11:09 ET | 29096 | 1.505 |
11:11 ET | 6500 | 1.495 |
11:13 ET | 13018 | 1.495 |
11:15 ET | 2900 | 1.495 |
11:18 ET | 1885 | 1.495 |
11:20 ET | 16448 | 1.485 |
11:22 ET | 2603 | 1.4795 |
11:24 ET | 1032 | 1.475 |
11:26 ET | 2815 | 1.49 |
11:27 ET | 400 | 1.49 |
11:29 ET | 2597 | 1.5 |
11:31 ET | 1000 | 1.5 |
11:33 ET | 1873 | 1.505 |
11:36 ET | 14800 | 1.51 |
11:38 ET | 14492 | 1.495 |
11:40 ET | 2600 | 1.5 |
11:44 ET | 2500 | 1.495 |
11:45 ET | 9300 | 1.4904 |
11:49 ET | 1700 | 1.495 |
11:51 ET | 5455 | 1.495 |
11:54 ET | 200 | 1.495 |
11:56 ET | 200 | 1.5 |
11:58 ET | 300 | 1.5 |
12:00 ET | 4100 | 1.5002 |
12:02 ET | 1500 | 1.505 |
12:03 ET | 10410 | 1.5 |
12:05 ET | 1700 | 1.5 |
12:09 ET | 500 | 1.4999 |
12:12 ET | 400 | 1.5 |
12:14 ET | 1297 | 1.495 |
12:18 ET | 565 | 1.5 |
12:20 ET | 1900 | 1.495 |
12:21 ET | 2960 | 1.495 |
12:23 ET | 1200 | 1.5 |
12:25 ET | 4620 | 1.505 |
12:27 ET | 200 | 1.51 |
12:30 ET | 6000 | 1.51 |
12:32 ET | 500 | 1.51 |
12:34 ET | 3647 | 1.51 |
12:36 ET | 4500 | 1.51 |
12:38 ET | 18851 | 1.52 |
12:39 ET | 60652 | 1.5 |
12:41 ET | 500 | 1.505 |
12:43 ET | 14035 | 1.49 |
12:45 ET | 800 | 1.495 |
12:50 ET | 1000 | 1.495 |
12:52 ET | 200 | 1.495 |
12:54 ET | 520 | 1.495 |
12:56 ET | 300 | 1.5 |
12:57 ET | 103 | 1.495 |
12:59 ET | 4300 | 1.495 |
01:01 ET | 1086 | 1.5 |
01:03 ET | 144 | 1.5 |
01:06 ET | 1675 | 1.4912 |
01:08 ET | 659 | 1.5 |
01:10 ET | 300 | 1.5 |
01:12 ET | 8548 | 1.505 |
01:14 ET | 2200 | 1.505 |
01:15 ET | 100 | 1.51 |
01:19 ET | 800 | 1.51 |
01:21 ET | 62381 | 1.505 |
01:24 ET | 350 | 1.505 |
01:26 ET | 900 | 1.505 |
01:28 ET | 4069 | 1.505 |
01:30 ET | 2100 | 1.5 |
01:32 ET | 4436 | 1.5089 |
01:33 ET | 400 | 1.505 |
01:37 ET | 500 | 1.505 |
01:39 ET | 1900 | 1.505 |
01:42 ET | 100 | 1.505 |
01:44 ET | 200 | 1.505 |
01:46 ET | 200 | 1.505 |
01:48 ET | 1800 | 1.505 |
01:50 ET | 10911 | 1.51 |
01:51 ET | 400 | 1.51 |
01:53 ET | 530 | 1.51 |
01:55 ET | 2500 | 1.51 |
01:57 ET | 1353 | 1.51 |
02:00 ET | 1100 | 1.51 |
02:04 ET | 100 | 1.51 |
02:08 ET | 100 | 1.51 |
02:11 ET | 900 | 1.51 |
02:13 ET | 2263 | 1.501 |
02:15 ET | 13000 | 1.505 |
02:18 ET | 100 | 1.5001 |
02:20 ET | 100 | 1.51 |
02:22 ET | 1300 | 1.51 |
02:24 ET | 19633 | 1.51 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 109.9M | 7.6x | --- |
Spero Therapeutics Inc | 78.0M | 3.5x | --- |
2Seventy Bio Inc | 245.2M | -1.1x | --- |
Fortress Biotech Inc | 44.9M | -0.3x | --- |
Rigel Pharmaceuticals Inc | 185.9M | -9.8x | --- |
G1 Therapeutics Inc | 169.4M | -5.5x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $109.9M |
---|---|
Revenue (TTM) | $119.2M |
Shares Outstanding | 77.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $0.20 |
Book Value | $-0.70 |
P/E Ratio | 7.6x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | 5.9x |
Operating Margin | 9.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.